MannKind

MannKind Corp. operates as a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MannKind reports strong Q4 earnings, eyes revenue growth opportunities

MannKind's strong financial performance in Q4 2022, driven by revenue growth and improved margins, positions the company for future success.
While challenges exist in healthcare innovation and regulatory processes, MannKind's focus on internal innovation and revenue diversification presents growth opportunities.
Opportunities in collaborations, inhaled therapeutics, and data-driven healthcare outcomes offer avenues for MannKind's future expansion and profitability.
Maintaining financial stability, driving revenue growth, and exploring new product opportunities are key strategies for MannKind's long-term success.

MannKind reports strong Q1 performance, eyes revenue growth opportunities

MannKind's Q1 2023 earnings call highlighted strong performance in royalty revenue, endocrine business, and liquidity position. Challenges include maintaining growth amidst competition, while opportunities lie in revenue growth and strategic collaborations. Overall, MannKind's positive outlook is supported by its pipeline progress and focus on shareholder value.

MannKind achieves first operating income, eyes international expansion for growth

MannKind's Q2 performance reflects significant financial milestones, with revenue growth, operating income, and strong gross margins showcasing operational efficiency and progress towards profitability.
While facing challenges such as trial costs and regulatory requirements, the company's strategic strengths in product expansion, R&D investments, and international partnerships position it for long-term growth.
Opportunities in strong patient demand, international market expansion, orphan lung areas, and product growth present avenues for revenue diversification and sustained performance.
Overall, MannKind's focus on innovation, financial sustainability, and market expansion sets a positive trajectory for future growth and profitability.

MannKind achieves first profitable quarter with strong revenue growth

MannKind's Q3 marked a profitable quarter with significant revenue growth and operational improvements.
Strengths include revenue diversification, margin enhancements, and promising trial progress.
Challenges lie in stabilizing V-Go revenue, fluctuating earnings, and trial design adjustments.
Opportunities include upcoming milestones, market leverage, and Medicare changes for growth.

MannKind reports record 2023 revenues, eyes growth opportunities in 2024

MannKind had a strong financial performance in 2023, with a focus on debt repayment, clinical trials, and shareholder value in 2024. Innovation in powders and NTM asset, along with strategic positioning and sales force optimization, offer growth potential.

MannKind reports record revenue in Q2 2024 earnings call

MannKind's Q2 2024 performance reflects strong revenue growth and progress on key products.
While facing challenges in IP protection and manufacturing capacity, the company maintains a healthy cash position.
Opportunities lie in upcoming milestones and market expansion, with a focus on enhancing financial performance.

MannKind reports record revenue, shifts focus to growth strategies

MannKind delivered strong financial performance, focusing on growth and innovation in its product portfolio. While transitioning Afrezza's mindset poses challenges, strategic investments and market expansion present promising opportunities for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Investors are hyperventilating after a delay for its inhaled medicine.

Why Shares of MannKind Corporation Are Falling This Morning

MannKind (MNKD) stock is taking a beating on Monday after releasing an update to investors concerning news from the FDA for Tyvaso DPI. The post MNKD Stock: The Disappointing FDA News That Has MannKind Shares Diving Today appeared first on InvestorPlace.

MNKD Stock: The Disappointing FDA News That Has MannKind Shares Diving Today

Shares of MannKind Corp. MNKD, -17.68% tumbled 18.3% in trading on Monday after the company said the Food and Drug Administration would not approve a pulmonary arterial hypertension treatment it is developing with United Therapeutics Corp. UTHR, -2.50% . United's stock was down 2.6%.

MannKind's stock falls 18% after FDA says it will not approve application for hypertension drug

MannKind Corp (NASDAQ: MNKD) is trading significantly lower Monday morning after the company announced the FDA issued a complete response to United Therapeutics regarding the New Drug Application for Tyvaso DPI. The FDA declined to approve the New Drug Application, citing a deficiency related to an open inspection issue at a third-party analytical testing center for treprostinil drug substance, the active ingredient of Tyvaso DPI.

Why MannKind Shares Are Falling Today

United Therapeutics

The FDA has issued a complete response to United Therapeutics Corporation (NASDAQ: UTHR) regarding the marketing application for Tyvaso DPI for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA's letter noted only a single deficiency related to an open inspection issue at a third-party facility that performs analytical testing of the treprostinil drug substance.

FDA Declines MannKind - United Therapeutics' Formulated Treprostinil For Lung Disease

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Oct. 18, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, has learned that the U.S. Food and Drug Administration (FDA) issued a complete response to United Therapeutics Corporation regarding the New Drug Application (NDA) for Tyvaso DPI™ for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA declined to approve the NDA at this time, noting only one deficiency related to an open inspection issue at a third-party analytical testing center for treprostinil drug substance, the active ingredient of Tyvaso DPI. The complete response did not pertain to MannKind, and no issues were cited by the FDA as it relates to MannKind's facility in Connecticut for manufacturing, testing and packaging of finished Tyvaso DPI, including its associated device.

Progress Update on Tyvaso DPI™ New Drug Application

MannKind Corporation (MNKD) CEO Mike Castagna Presents at Lytham Partners Fall Conference (Transcript)

Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.

Do Options Traders Know Something About MannKind (MNKD) Stock We Don't?

WESTLAKE VILLAGE, Calif., Oct. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today the enrollment of the first pediatric patient in the INHALE-1 study.

MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population

Arbutus Biopharma

Adverum Biotechnologies

Kaleido Biosciences Inc

Trevena

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has entered into a sale-leaseback transaction with an affiliate of Creative Manufacturing Properties, which will generate $102.25 million in gross proceeds upon closing.

Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds

WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it will be participating at the Lytham Partners Fall 2021 Investor Conference on Tuesday, October 5, 2021 at 11:45 am (ET). Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD.

MannKind Corporation to Participate at Lytham Partners Fall 2021 Investor Conference

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Cantor Global Healthcare 2021 Conference (Transcript)

MannKind Corporation (MNKD) CEO Michael Castagna Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit (Transcript)

MannKind Corporation (MNKD) CEO Michael Castagna Presents at H.C. Wainwright 23rd Annual Global Investment Brokers Conference (Transcript)

WESTLAKE VILLAGE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright 23rd Annual Global Investment Conference which will be available on demand starting on September 13, 2021.

MannKind Corporation to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

BIOLASE

Meta Materials

Romeo Power

Inuvo

DatChat

Investing in penny stocks can be an intriguing numbers game. With many stocks to choose from, a handful are bound to be winners.

The 6 Best Penny Stocks to Buy for September

Qumu Corp.

Surgalign Holdings, Inc.

Insiders are buying these penny stocks right now. Should you?

8 Best Penny Stocks To Buy Right Now According To Insiders

Aerpio Pharmaceuticals Inc

Micronet Enertec Technologies

RLX Technology

Looking for penny stocks to buy now? The post Best Penny Stocks To Buy Right Now?

Best Penny Stocks To Buy Right Now? 5 To Watch Before September

MannKind Corporation (MNKD) CEO Michael Castagna on Q2 2021 Results - Earnings Call Transcript

Shares of MannKind (NASDAQ:MNKD) moved higher by 3.1% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% year over year to ($0.05), which missed the estimate of ($0.04).

MannKind: Q2 Earnings Insights

Conference Call to Begin Today at 5:00 PM ET

MannKind Corporation Reports 2021 Second Quarter Financial Results

NRX Pharmaceuticals

RADNOR, Pa., Aug. 4, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP), produced by the body to help protect cells against inflammatory conditions.

NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions

WESTLAKE VILLAGE, Calif., Aug. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) has partnered with NRx Pharmaceuticals (Nasdaq: NRXP) (NRx) to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP) – an endogenous substance produced by the body that helps protect cells against inflammatory conditions.

MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform

WESTLAKE VILLAGE, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2021 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August 11, 2021.

News for MannKind Stock (MNKD)